{"gene":"CDK9","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1994,"finding":"PITALRE (CDK9) is a nuclear CDC2-related serine/threonine protein kinase that phosphorylates the retinoblastoma protein (pRb) in vitro but cannot phosphorylate histone H1, indicating a substrate specificity distinct from CDC2. It associates with three cellular polypeptides of 80, 95, and 155 kDa and localizes primarily to the nucleus.","method":"Immunoprecipitation-associated in vitro kinase assay, immunofluorescence, cDNA cloning","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with clear substrate discrimination, replicated across subsequent studies, foundational paper","pmids":["8170997"],"is_preprint":false},{"year":1996,"finding":"PITALRE (CDK9) is the catalytic subunit responsible for kinase activity in its multimeric complexes, demonstrated using a catalytically inactive mutant. Monomeric CDK9 is active in vitro but PITALRE in multimeric complexes exhibits several-fold higher activity, suggesting regulatory proteins modulate its activity and/or substrate recognition.","method":"Dominant-negative catalytic mutant overexpression, in vitro kinase assay, protein complex characterization","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — catalytic mutant reconstitution experiment directly establishing CDK9 as the catalytic subunit","pmids":["8870681"],"is_preprint":false},{"year":1996,"finding":"PITALRE (CDK9) is a Ser/Thr proline-directed kinase. It phosphorylates myelin basic protein (MBP) on Ser-162 (a proline-directed residue) and Thr-97, with substrate site specificity distinguishable from CDC2 and CDK2.","method":"In vitro kinase assay with phosphopeptide mapping and phosphoamino acid analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro phosphorylation site mapping with multiple independent antibodies confirming identical activities","pmids":["9003389"],"is_preprint":false},{"year":1997,"finding":"PITALRE (CDK9)-associated kinase activity phosphorylates pRb exclusively on serine residues at sites similar to those phosphorylated by CDC2 kinase in vitro.","method":"In vitro kinase assay with phosphoamino acid analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — single in vitro experiment confirming serine-only phosphorylation of pRb, single lab","pmids":["9258347"],"is_preprint":false},{"year":1998,"finding":"PITALRE (CDK9) is the catalytic subunit of the Tat-associated kinase (TAK) and is required for HIV-1 Tat transactivation in vivo. A catalytic mutant (D167N) more efficiently squelches Tat transactivation than wild-type CDK9. Artificial tethering of PITALRE to a nascent RNA element, in the absence of Tat, activates HIV-1 LTR expression.","method":"Transient overexpression, catalytic mutant analysis, artificial RNA-tethering assay, HIV-1 LTR reporter assays","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal experiments (dominant-negative, artificial tethering, integrated and transfected reporters) establishing CDK9 as mediator of Tat transactivation","pmids":["9557739"],"is_preprint":false},{"year":2001,"finding":"CDK9 and cyclin T1 localize throughout the non-nucleolar nucleoplasm and concentrate at nuclear speckles that are enriched in splicing factors. The pattern is altered by transcription inhibitors. A central region of cyclin T1 mediates speckle accumulation and can recruit CDK9 and HIV Tat to this compartment.","method":"High-resolution immunofluorescence microscopy, cyclin T1 deletion mutants, co-expression experiments","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiment with functional domain mapping and pharmacological perturbation, replicated with multiple antibodies and deletion constructs","pmids":["11282025"],"is_preprint":false},{"year":2003,"finding":"A novel protein MAQ1 (HEXIM1) associates with the inactive P-TEFb complex in a manner dependent on 7SK snRNA. MAQ1 binds directly to the N-terminal cyclin homology region of cyclin T1 and T2, and this 7SK RNA/MAQ1 association competes with Tat binding to cyclin T1. Transcription inhibition releases both MAQ1 and 7SK RNA from P-TEFb, indicating a dynamic regulatory mechanism for CDK9 activity.","method":"Co-immunoprecipitation, yeast two-hybrid, transcription inhibitor treatment, protein complex characterization","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP plus yeast two-hybrid, identifying binding domain and competitive interaction; replicated across labs","pmids":["12832472"],"is_preprint":false},{"year":2003,"finding":"CDK9 protein levels are constitutively expressed throughout the cell cycle and are not regulated by the SCF(SKP2) ubiquitin ligase. Endogenous CDK9 is a stable protein (half-life 4–7 h), while overexpressed CDK9 is rapidly degraded (half-life <1 h). CDK9 kinase activity does not oscillate during the cell cycle.","method":"Cell cycle synchronization experiments, cycloheximide chase, SKP2 siRNA knockdown, proteasome inhibitor treatment, Western blot","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (synchronization, knockdown, inhibitors) consistently showing cell cycle-independent expression and activity","pmids":["12861003"],"is_preprint":false},{"year":2004,"finding":"CDK9 (as part of P-TEFb) is recruited by STAT3 to the p21waf1 promoter to phosphorylate the CTD of RNA polymerase II at serine 2, enabling transcription elongation. BRG1 is recruited first to remodel chromatin, followed by CDK9 recruitment to drive elongation at the STAT3 target gene.","method":"Co-immunoprecipitation, pull-down, chromatin immunoprecipitation (ChIP), Southern blot accessibility assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and Co-IP demonstrate ordered recruitment, single lab with two orthogonal methods","pmids":["15286705"],"is_preprint":false},{"year":2005,"finding":"CDK9 has two isoforms, 42k and 55k. Both isoforms phosphorylate the CTD of RNA polymerase II with identical phosphorylation patterns on 144 peptide substrates. CDK9-42k localizes diffusely in the nucleoplasm while CDK9-55k accumulates in the nucleolus. Expression of the 55k isoform is induced upon macrophage differentiation while the 42k isoform predominates in activated lymphocytes.","method":"Immunofluorescence, kinase assay with peptide array, immunoblot of primary cells, promoter reporter assay","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — differential localization established by direct imaging with multiple orthogonal methods including kinase assay and primary cell analysis","pmids":["15452830"],"is_preprint":false},{"year":2005,"finding":"The Cdk9(55) isoform is localized to the nucleus and is expressed as the predominant form in primary rat hepatocytes; as cells enter the cell cycle, CDK9(42) expression is induced and becomes the major form while CDK9(55) remains relatively constant. The relative abundance of the two isoforms varies across mouse tissues.","method":"Immunofluorescence, Western blot of murine tissues and primary hepatocytes, tetracycline-inducible expression","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization and expression profiling in primary cells and tissues, single lab","pmids":["15780980"],"is_preprint":false},{"year":2010,"finding":"CDK9 phosphorylates the androgen receptor (AR) on serine 81 (S81) in vitro in a site-specific manner. CDK9 co-immunoprecipitates with AR. Overexpression of CDK9 with cyclin T increases S81 phosphorylation; CDK9 siRNA knockdown and CDK9 inhibitors reduce hormone-induced S81 phosphorylation. S81 phosphorylation regulates AR promoter selectivity and cell growth.","method":"In vitro kinase assay, co-immunoprecipitation, mass spectrometry, siRNA knockdown, pharmacological inhibition, reporter assay","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay plus multiple cellular validation approaches (siRNA, OE, inhibitors), single lab with multiple orthogonal methods","pmids":["20980437"],"is_preprint":false},{"year":2011,"finding":"CDK9 in complex with cyclin K (not cyclin T) directly functions in maintaining genome integrity in response to replication stress. CDK9-cyclin K (but not CDK9-cyclin T) depletion impairs cell cycle recovery after replication stress, induces spontaneous DNA damage, and CDK9 accumulates on chromatin to limit single-stranded DNA accumulation. CDK9-cyclin K interacts with ATR and DNA damage response proteins.","method":"Cyclin-specific siRNA depletion, DNA damage assays, chromatin fractionation, co-immunoprecipitation, cell cycle analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — cyclin-specific depletion distinguishes CDK9-cyclin K from CDK9-cyclin T function, multiple orthogonal readouts","pmids":["21200140"],"is_preprint":false},{"year":2013,"finding":"CDK9 physically interacts with Pirh2 and phosphorylates it on Ser-211 and Thr-217, rendering Pirh2 inactive and contributing to p53 stabilization. CDK9 also promotes phosphorylation of Mdm2 on Ser-395, preventing Mdm2-mediated p53 degradation.","method":"Co-immunoprecipitation, in vitro kinase assay, Western blot, site-directed mutagenesis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay and co-IP, single lab, no independent replication","pmids":["23603988"],"is_preprint":false},{"year":2017,"finding":"CDK9 activity decreases the pause duration of promoter-proximally paused RNA Pol II and increases productive initiation frequency, demonstrating that CDK9 stimulates release of paused polymerase and activates transcription by increasing the number of transcribing polymerases and the amount of mRNA synthesized. CDK9 activity is also associated with long-range chromatin interactions.","method":"Chemical-genetic CDK9 inhibition in engineered human cells combined with multi-omics (transient transcriptome sequencing, 4sU-seq, Hi-C)","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-omics approach with specific rapid CDK9 inhibition in engineered cells, quantitative mechanistic dissection","pmids":["28994650"],"is_preprint":false},{"year":2017,"finding":"SIRT7 deacetylates CDK9 at lysine 48, counteracting GCN5-mediated acetylation, which activates CDK9 kinase activity to phosphorylate Pol II CTD serine 2 and promote transcription elongation. SIRT7 also promotes release of P-TEFb from the inactive 7SK snRNP complex.","method":"Proteomic identification of SIRT7 substrates, co-immunoprecipitation, in vitro deacetylation assay, CTD phosphorylation assay, SIRT7 depletion","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro deacetylation assay combined with in-cell validation and identification of the modifying enzymes (SIRT7 and GCN5), multiple methods","pmids":["28426094"],"is_preprint":false},{"year":2017,"finding":"THAL-SNS-032, a CDK9 degrader (PROTAC with thalidomide moiety recruiting Cereblon E3 ligase), selectively degrades CDK9 without affecting other SNS-032 targets, demonstrating that CDK9 degradation induces distinct and prolonged pharmacological effects (including irreversible apoptosis after washout) compared with CDK9 kinase inhibition alone.","method":"PROTAC-mediated targeted protein degradation, washout experiments, transcriptome profiling, cell viability assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — selective degrader vs. inhibitor comparison with transcriptome profiling and functional assays, multiple orthogonal methods","pmids":["29251720"],"is_preprint":false},{"year":2018,"finding":"SUMO suppresses global transcription by promoting sumoylation of CDK9, which blocks CDK9 interaction with Cyclin T1 and thus prevents formation of the active P-TEFb complex. MYC antagonizes CDK9 sumoylation to amplify global transcription. A sumoylation-resistant CDK9 mutant confirms that CDK9 sumoylation inhibits global transcription.","method":"SUMO-MS, SUMOylation assays, co-immunoprecipitation, sumoylation-resistant mutant, transcription profiling","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro SUMOylation assays, mutagenesis with sumoylation-resistant mutant, and transcription profiling in same study","pmids":["29588524"],"is_preprint":false},{"year":2018,"finding":"CDK9 inhibition dephosphorylates the SWI/SNF protein BRG1 and contributes to reactivation of epigenetically silenced genes including tumor suppressor genes in cancer cells. CDK9 is essential for maintaining gene silencing at heterochromatic loci in addition to its role in transcription elongation.","method":"Live cell drug screen with genetic confirmation, siRNA knockdown, pharmacological inhibition, gene expression analysis, ChIP","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological validation with multiple cancer models, identification of BRG1 as substrate","pmids":["30454645"],"is_preprint":false},{"year":2019,"finding":"TRIM28 SUMOylates CDK9 at lysines 44, 56, and 68 (using SUMO4), which inhibits CDK9 kinase activity and/or prevents P-TEFb assembly by blocking CDK9-Cyclin T1 interaction, thereby suppressing HIV-1 transcription and contributing to viral latency.","method":"Global site-specific SUMO-MS, serial SUMOylation assays, kinase activity assays, co-immunoprecipitation, site-directed mutagenesis of SUMOylation sites","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — mass spectrometry identification of SUMOylation sites confirmed by serial biochemical assays and mutagenesis, mechanistic consequence on P-TEFb assembly demonstrated","pmids":["30652970"],"is_preprint":false},{"year":2019,"finding":"CDK9 forms novel complexes (CTORC1 and CTORC2) with mTOR scaffold protein mLST8. In the nucleus, CDK9-RAPTOR-mLST8 (CTORC1) promotes transcription of leukemogenic genes. In the cytoplasm, CDK9-RICTOR-SIN1-mLST8 (CTORC2) controls mRNA translation through phosphorylation of LARP1 and rpS6.","method":"Proteomics/mass spectrometry of mTOR complex interactors, co-immunoprecipitation, subcellular fractionation, phosphorylation assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic identification with co-IP validation, single lab, novel finding not yet independently replicated","pmids":["30587525"],"is_preprint":false},{"year":2019,"finding":"CDK9 modulates the circadian clock by physically associating with REV-ERBα and attenuating its binding to the RORE element in the Bmal1 promoter. CDK9 knockdown in the anterior hypothalamus (SCN region) in mice alters respiratory exchange ratio, daily activity, and circadian period.","method":"siRNA screen, CDK9 siRNA knockdown, co-immunoprecipitation, in vivo hypothalamic knockdown, circadian phenotype measurement","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of CDK9-REV-ERBα with in vivo knockdown phenotype, single lab","pmids":["31005255"],"is_preprint":false},{"year":2020,"finding":"CDK9 (P-TEFb) phosphorylates PP1 and PP4 phosphatase complexes (inhibitory phosphorylation), creating two distinct kinase-phosphatase switches: PP4 governs pause release at the 5' end of genes by dephosphorylating Spt5-Ser666 and the Spt5 CTR, while PP1 governs the elongation-termination transition at gene 3' ends by dephosphorylating the Spt5 CTR. Depletion of PP4 complex subunits redistributes paused Pol II into gene bodies.","method":"Kinase-phosphatase depletion experiments, phosphoproteomics, ChIP-seq, in vivo Spt5 phosphorylation analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (depletion, phosphoproteomics, ChIP-seq) identifying two distinct substrate-specific kinase-phosphatase switches","pmids":["32859893"],"is_preprint":false},{"year":2020,"finding":"CDK9 inhibition globally impairs splicing of thousands of mRNAs in prostate cancer cells, with no coordinated response between alternative splicing and the transcriptome. CDK9 inhibition causes loss of androgen receptor (AR) and AR-v7 splice variant expression, sensitizing CRPC cells to androgen deprivation.","method":"RNA-seq, splicing analysis, CDK9 inhibitor treatment, AR splice variant analysis, androgen deprivation assays","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptome-wide splicing analysis with CDK9-targeted inhibition in multiple prostate cancer cell lines, single lab","pmids":["34592899"],"is_preprint":false},{"year":2020,"finding":"Cdk9 inhibition or H2B mono-ubiquitination (H2Bub1) loss independently induces intragenic antisense transcription in fission yeast, affecting largely distinct gene subsets. Combined ablation de-represses antisense transcription of over half the genome. CDK9-dependence correlates with high H2Bub1 occupancy. Combined perturbation impairs Clr6-CII (HDAC) recruitment and increases histone acetylation in coding regions.","method":"Chemical-genetic Cdk9 inhibition, H2Bub1 loss epistasis, genome-wide nascent RNA sequencing, ChIP-seq, genetic interaction analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide epistasis between Cdk9 and H2Bub1 with mechanistic link to Clr6-CII HDAC recruitment, multiple orthogonal methods","pmids":["32496538"],"is_preprint":false},{"year":2020,"finding":"ASF1B forms stable complexes with CDK9 and positively regulates CDK9 protein stability, functioning as an oncogenic stabilizer of CDK9 in cervical cancer cells.","method":"Co-immunoprecipitation, siRNA knockdown, overexpression, xenograft models","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP establishing complex, stability mechanism not biochemically confirmed with ubiquitin/proteasome assays, single lab","pmids":["32848135"],"is_preprint":false},{"year":2021,"finding":"A PP2A complex recruited to transcription sites by Integrator complex subunit INTS6 dynamically antagonizes CDK9-mediated phosphorylation of key substrates including DSIF and RNAPII-CTD. Loss of INTS6 results in resistance to CDK9 inhibition and amplification of acute oncogenic transcriptional responses. Pharmacological PP2A activation synergizes with CDK9 inhibition.","method":"INTS6 loss-of-function, phosphoproteomic analysis of CDK9 substrates, pharmacological PP2A activation, cell viability assays, in vivo tumor models","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate-specific phosphoproteomics with genetic loss-of-function and pharmacological validation, in vivo confirmation","pmids":["34004147"],"is_preprint":false},{"year":2021,"finding":"CDK9 inhibits CDK9 substrates including SF3B1 (splicing factor), and inhibition causes loss of SF3B1 and polyadenylation factors from chromatin. CDK9 inhibition also causes premature transcription termination across the last exon and loss of polyadenylation of nascent transcripts. PP2A inhibition rescues premature termination caused by CDK9 inhibition, placing CDK9 and PP2A as opposing regulators of coupled transcription elongation, termination, and RNA processing.","method":"CDK9 inhibition and PP2A inhibition, ChIP-seq, metabolic RNA labeling, polyadenylation factor chromatin occupancy assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistatic rescue experiment (PP2A inhibition rescuing CDK9 inhibition phenotypes) plus direct chromatin occupancy measurements, multiple orthogonal methods","pmids":["35980303"],"is_preprint":false},{"year":2021,"finding":"CSN6 stabilizes CDK9 protein by reducing CDK9 ubiquitination levels. The E3 ligase UBR5 is negatively regulated by CSN6 and promotes ubiquitination and degradation of CDK9. The CSN6-UBR5-CDK9 axis promotes melanoma proliferation and metastasis.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, overexpression, xenograft models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay with genetic epistasis (UBR5 KD rescuing CSN6 KD), identification of E3 ligase, single lab","pmids":["33483464"],"is_preprint":false},{"year":2017,"finding":"BRCA1 recruitment to DNA damage sites (ionizing radiation-induced foci) is dependent on CDK9. CDK9 interacts with endogenous BRCA1 and BARD1 through RING finger and BRCT domains, forms IRIF at DNA damage sites, and co-localizes with BRCA1. CDK9-deficient cells show altered γ-H2AX dynamics, reduced HR efficiency, and failure to form BRCA1 and RAD51 IRIF.","method":"Co-immunoprecipitation, immunofluorescence microscopy of IRIF, CDK9 siRNA knockdown, HR/NHEJ repair assays, genotoxic sensitivity assays","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP for interaction plus functional DNA repair assays, multiple readouts, single lab","pmids":["28278048"],"is_preprint":false},{"year":2019,"finding":"Using analog-sensitive CDK9 combined with quantitative phosphoproteomics, 1,102 phosphosites and 120 potential cellular CDK9 substrates were identified. A substantial number of CDK9 substrates are splicing factors, establishing CDK9's role in transcription-coupled splicing. Cellular context fundamentally impacts CDK9 substrate selection compared to in vitro data.","method":"Analog-sensitive kinase technology, quantitative phosphoproteomics, chemical-genetic inhibition","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1 / Strong — analog-sensitive kinase combined with quantitative mass spectrometry, direct identification of cellular CDK9 substrates at proteome scale","pmids":["31857848"],"is_preprint":false},{"year":2023,"finding":"NELF-mediated promoter-proximal pausing establishes a strict checkpoint requiring Cdk9 kinase activity for pause release into productive elongation. In NELF-depleted cells, Cdk9 inhibition does not efficiently shut down gene transcription but instead allows defective, non-productive transcription to continue. Only NELF-dependent pausing creates this strict Cdk9 requirement.","method":"NELF depletion in Drosophila cells, chemical-genetic Cdk9 inhibition, nascent RNA sequencing, epistasis analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (NELF depletion) combined with specific chemical-genetic Cdk9 inhibition plus genome-wide transcription readout; mechanistically rigorous","pmids":["37179384"],"is_preprint":false},{"year":2023,"finding":"The CDK9 kinase domain mutation L156F confers resistance to CDK9 inhibitors including both ATP-competitive inhibitors and PROTAC degraders by causing steric hindrance to inhibitor binding and altering CDK9 thermal stability and catalytic activity.","method":"Acquired resistance cell line, genomic sequencing, CRISPR/Cas9 knock-in, kinase activity assays, thermal shift assay","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR knock-in of resistance mutation with biochemical characterization of the mechanism, single lab","pmids":["37719386"],"is_preprint":false},{"year":2023,"finding":"OTUD1 deubiquitinase binds CDK9 and catalyzes K63-linked deubiquitination on CDK9 (with Cys320 of OTUD1 being critical), promoting CDK9 phosphorylation and activation to induce inflammatory responses and fibrosis in kidney epithelial cells.","method":"Co-immunoprecipitation, deubiquitination assay with OTUD1 catalytic mutant, Otud1 knockout mice, CDK9 inhibitor treatment, phosphorylation assays","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deubiquitination assay with catalytic mutant identifying specific linkage type, in vivo Otud1 KO validation, single lab","pmids":["38110583"],"is_preprint":false}],"current_model":"CDK9, the catalytic subunit of P-TEFb (complexed with cyclin T1, T2, or K), is a nuclear serine/threonine proline-directed kinase that phosphorylates the Ser2 residue of the RNAPII CTD heptad repeat and the negative elongation factors DSIF/Spt5 and NELF to release promoter-proximally paused RNA polymerase II into productive transcription elongation; its activity is regulated by dynamic inhibitory sequestration in the 7SK snRNP complex (through HEXIM1/MAQ1 and 7SK RNA binding cyclin T), by post-translational modifications including phosphorylation, acetylation by GCN5 (inactivating) and deacetylation by SIRT7 (activating), and SUMOylation by TRIM28 (blocking Cyclin T1 interaction); CDK9 is opposed by PP2A (recruited via INTS6) and PP4 phosphatase complexes that dephosphorylate CDK9 substrates to govern pause release and elongation-termination transitions, respectively; additionally, CDK9-cyclin K (distinct from the P-TEFb cyclin T complexes) functions in genome integrity maintenance in response to replication stress by interacting with ATR; CDK9 also phosphorylates non-transcription substrates including the androgen receptor (Ser81), Pirh2 (Ser211/Thr217), and splicing factors, and its protein stability is regulated by UBR5-mediated ubiquitination (counteracted by CSN6) and OTUD1-mediated K63 deubiquitination."},"narrative":{"mechanistic_narrative":"CDK9 is a nuclear, proline-directed serine/threonine kinase and the catalytic subunit of multimeric complexes whose principal cellular role is to release promoter-proximally paused RNA polymerase II into productive transcription elongation [PMID:8170997, PMID:8870681, PMID:9003389, PMID:28994650]. As the kinase of P-TEFb (with cyclin T), it phosphorylates the RNA Pol II CTD on serine 2 and is recruited to target genes such as p21 and HIV-1 LTR by sequence-specific factors and chromatin remodelers, where it shortens pause duration and increases productive initiation [PMID:9557739, PMID:15286705, PMID:28994650]; at NELF-dependent paused genes its activity is a strict checkpoint required for productive elongation [PMID:37179384]. CDK9 establishes substrate-specific kinase-phosphatase switches by inhibitory phosphorylation of PP1 and PP4, controlling both pause release and the elongation-to-termination transition through Spt5, and is dynamically opposed by INTS6-recruited PP2A on DSIF and the CTD [PMID:32859893, PMID:34004147, PMID:35980303]. Through a large cohort of cellular substrates dominated by splicing factors (including SF3B1), CDK9 couples elongation to co-transcriptional RNA processing, polyadenylation, and splicing [PMID:31857848, PMID:35980303, PMID:34592899]. Its activity is gated by inhibitory sequestration in the 7SK snRNP via HEXIM1/MAQ1 binding to cyclin T [PMID:12832472] and by reversible modifications: SIRT7-mediated deacetylation (opposing GCN5) activates the kinase [PMID:28426094], while SUMOylation—including TRIM28-catalyzed SUMOylation—blocks the CDK9–cyclin T1 interaction to suppress global and HIV-1 transcription [PMID:29588524, PMID:30652970]. CDK9 protein levels are set by ubiquitin-dependent turnover, with UBR5 promoting degradation (counteracted by CSN6) and OTUD1 stabilizing and activating CDK9 by K63 deubiquitination [PMID:33483464, PMID:38110583]. Beyond transcription, a distinct CDK9–cyclin K complex maintains genome integrity under replication stress in association with ATR [PMID:21200140], CDK9 supports BRCA1/RAD51 focus formation and homologous recombination at DNA damage sites [PMID:28278048], and it phosphorylates non-transcriptional targets including androgen receptor Ser81 and the p53 regulator Pirh2 [PMID:20980437, PMID:23603988].","teleology":[{"year":1994,"claim":"Established CDK9 as a nuclear CDC2-related kinase with substrate specificity distinct from CDC2, answering whether it was a generic cell-cycle CDK or a functionally separate enzyme.","evidence":"cDNA cloning, immunoprecipitation in vitro kinase assay, and immunofluorescence","pmids":["8170997"],"confidence":"High","gaps":["Physiological substrates and partner subunits not yet identified","The 80/95/155 kDa associated polypeptides not molecularly defined"]},{"year":1996,"claim":"Demonstrated CDK9 is the catalytic subunit of its complexes and a proline-directed Ser/Thr kinase whose activity is enhanced by associated regulatory proteins, defining it as a regulated holoenzyme.","evidence":"Catalytically inactive mutant reconstitution and in vitro phosphosite mapping","pmids":["8870681","9003389"],"confidence":"High","gaps":["Identity of the activating regulatory subunits (cyclins) not established","In vivo substrates unknown"]},{"year":1998,"claim":"Linked CDK9 to gene-specific transcriptional activation by showing it is the catalytic subunit of Tat-associated kinase required for HIV-1 transactivation, with RNA-tethering sufficient to activate the LTR.","evidence":"Dominant-negative mutant, artificial RNA-tethering, and LTR reporter assays","pmids":["9557739"],"confidence":"High","gaps":["Direct CTD phosphorylation mechanism not yet shown","Endogenous cellular promoters not tested"]},{"year":2001,"claim":"Resolved subnuclear distribution by showing CDK9/cyclin T1 concentrate at splicing-factor-rich nuclear speckles in a transcription-dependent manner, hinting at coupling between elongation and RNA processing.","evidence":"High-resolution immunofluorescence with cyclin T1 deletion mapping and transcription inhibitors","pmids":["11282025"],"confidence":"High","gaps":["Functional consequence of speckle localization not established","Link to splicing only correlative at this stage"]},{"year":2003,"claim":"Defined a dynamic inhibitory control mechanism by identifying HEXIM1/MAQ1 as a 7SK snRNA-dependent binder of cyclin T1 that competes with Tat, explaining how active P-TEFb is sequestered and released.","evidence":"Reciprocal co-IP, yeast two-hybrid, and transcription-inhibitor release assays","pmids":["12832472"],"confidence":"High","gaps":["Signals triggering release from 7SK snRNP not defined","Stoichiometry of the inactive complex unresolved"]},{"year":2003,"claim":"Showed CDK9 expression and activity are constitutive across the cell cycle and not SCF(SKP2)-regulated, distinguishing it from oscillating cell-cycle CDKs.","evidence":"Synchronization, cycloheximide chase, SKP2 knockdown, and proteasome inhibition","pmids":["12861003"],"confidence":"High","gaps":["The E3 ligase governing endogenous turnover not identified here","Discrepancy between endogenous and overexpressed protein stability unexplained"]},{"year":2004,"claim":"Connected CDK9 to ordered gene activation by showing STAT3 recruits P-TEFb to phosphorylate Pol II CTD-Ser2 at p21 after BRG1-mediated chromatin remodeling.","evidence":"Co-IP, pull-down, and ChIP at the p21 promoter","pmids":["15286705"],"confidence":"Medium","gaps":["Single-lab, two-method support","Generality across STAT3 targets not tested"]},{"year":2005,"claim":"Identified two CDK9 isoforms (42k/55k) with identical CTD-kinase activity but distinct localization and differentiation-regulated expression, indicating isoform-specific deployment.","evidence":"Immunofluorescence, peptide-array kinase assays, and primary-cell/tissue immunoblotting","pmids":["15452830","15780980"],"confidence":"High","gaps":["Distinct biological functions of the nucleolar 55k isoform not defined","Mechanism directing differential localization unknown"]},{"year":2010,"claim":"Extended CDK9 substrate range beyond transcription machinery by identifying androgen receptor Ser81 as a site controlling AR promoter selectivity and growth.","evidence":"In vitro kinase assay, co-IP, mass spectrometry, siRNA, and inhibitor/reporter assays","pmids":["20980437"],"confidence":"High","gaps":["Whether P-TEFb or another CDK9 complex performs this phosphorylation in vivo not fully resolved","Cyclin partner dependence not dissected"]},{"year":2011,"claim":"Distinguished a non-transcriptional CDK9 function by showing CDK9–cyclin K (not cyclin T) maintains genome integrity after replication stress in association with ATR.","evidence":"Cyclin-specific siRNA depletion, DNA damage assays, chromatin fractionation, and co-IP","pmids":["21200140"],"confidence":"High","gaps":["Direct CDK9-cyclin K substrates in the replication stress response not identified","Mechanism of ATR cooperation unresolved"]},{"year":2013,"claim":"Implicated CDK9 in p53 stabilization by phosphorylating Pirh2 (Ser211/Thr217) to inactivate it and modifying Mdm2 to block p53 degradation.","evidence":"Co-IP, in vitro kinase assay, and site-directed mutagenesis","pmids":["23603988"],"confidence":"Medium","gaps":["Single lab, no independent replication","Cellular relevance and cyclin partner not established"]},{"year":2017,"claim":"Quantitatively dissected CDK9's elongation function, showing it shortens Pol II pause duration and increases productive initiation, and is linked to long-range chromatin interactions.","evidence":"Rapid chemical-genetic CDK9 inhibition in engineered cells with TT-seq, 4sU-seq, and Hi-C","pmids":["28994650"],"confidence":"High","gaps":["Causal basis of the chromatin-interaction link not established","Substrate(s) mediating initiation effects not pinpointed"]},{"year":2017,"claim":"Revealed acetylation control of CDK9 activity, with SIRT7 deacetylating Lys48 to activate the kinase and promote 7SK release, opposing GCN5-mediated inhibitory acetylation.","evidence":"Substrate proteomics, in vitro deacetylation, CTD phosphorylation assays, and SIRT7 depletion","pmids":["28426094"],"confidence":"High","gaps":["Signals controlling the acetylation/deacetylation balance not defined"]},{"year":2017,"claim":"Defined CDK9 as a chromatin-silencing factor by showing CDK9 inhibition dephosphorylates BRG1 and reactivates epigenetically silenced tumor suppressors, expanding its role beyond elongation.","evidence":"Live-cell drug screen, siRNA, inhibitors, ChIP, and expression analysis in cancer models","pmids":["30454645"],"confidence":"High","gaps":["Whether BRG1 phosphorylation directly mediates silencing not fully established"]},{"year":2017,"claim":"Connected CDK9 to homologous recombination by showing CDK9 interacts with BRCA1/BARD1 and is required for BRCA1 and RAD51 focus formation at DNA damage sites.","evidence":"Co-IP, IRIF imaging, siRNA knockdown, and HR/NHEJ repair assays","pmids":["28278048"],"confidence":"Medium","gaps":["Single lab; direct kinase activity on repair factors not demonstrated","Relationship to CDK9-cyclin K function unclear"]},{"year":2018,"claim":"Established SUMOylation as an inhibitory switch by showing SUMO-modified CDK9 cannot bind cyclin T1, with MYC antagonizing this to amplify global transcription.","evidence":"SUMO-MS, SUMOylation assays, sumoylation-resistant mutant, and transcription profiling","pmids":["29588524"],"confidence":"High","gaps":["SUMO E3 ligase not identified in this study","In vivo dynamics of CDK9 SUMOylation not mapped"]},{"year":2019,"claim":"Identified TRIM28 as the SUMO ligase modifying CDK9 (Lys44/56/68 via SUMO4) that blocks P-TEFb assembly and enforces HIV-1 latency.","evidence":"Site-specific SUMO-MS, serial SUMOylation/kinase assays, co-IP, and mutagenesis","pmids":["30652970"],"confidence":"High","gaps":["Stimuli regulating TRIM28-CDK9 SUMOylation in latent cells not defined"]},{"year":2019,"claim":"Proposed additional CDK9 complexes (CTORC1/2 with mTOR scaffold mLST8) coupling CDK9 to transcription of leukemogenic genes and to translation via LARP1/rpS6.","evidence":"Interactome proteomics, co-IP, fractionation, and phosphorylation assays","pmids":["30587525"],"confidence":"Medium","gaps":["Single lab, not independently replicated","Direct kinase activity toward LARP1/rpS6 vs. scaffold role not fully distinguished"]},{"year":2019,"claim":"Implicated CDK9 in circadian control by showing it associates with REV-ERBα and modulates Bmal1 promoter binding, with hypothalamic knockdown altering circadian physiology.","evidence":"siRNA screen, co-IP, and in vivo SCN knockdown with circadian phenotyping","pmids":["31005255"],"confidence":"Medium","gaps":["Single lab","Whether the effect requires CDK9 kinase activity not established"]},{"year":2019,"claim":"Mapped the cellular CDK9 substrate landscape at proteome scale, revealing splicing factors as a dominant substrate class and establishing transcription-coupled splicing as a core CDK9 function.","evidence":"Analog-sensitive CDK9 with quantitative phosphoproteomics","pmids":["31857848"],"confidence":"High","gaps":["Functional consequence of each substrate phosphorylation not individually validated"]},{"year":2020,"claim":"Defined CDK9 as the master kinase of dual kinase-phosphatase switches, inhibiting PP4 (pause release via Spt5) and PP1 (elongation-termination via Spt5 CTR) at distinct gene positions.","evidence":"Kinase-phosphatase depletion, phosphoproteomics, and ChIP-seq with Spt5 phospho-analysis","pmids":["32859893"],"confidence":"High","gaps":["How position-specific phosphatase targeting is achieved not fully resolved"]},{"year":2020,"claim":"Showed CDK9 inhibition globally impairs splicing and abolishes AR/AR-v7 expression, linking CDK9-dependent splicing to castration-resistant prostate cancer.","evidence":"RNA-seq, splicing analysis, CDK9 inhibition, and androgen deprivation assays","pmids":["34592899"],"confidence":"Medium","gaps":["Direct splicing-factor substrates driving the effect not pinpointed","Single lab"]},{"year":2020,"claim":"Demonstrated CDK9 cooperation with H2B monoubiquitination to suppress intragenic antisense transcription, linking CDK9 to HDAC (Clr6-CII) recruitment and chromatin integrity in coding regions.","evidence":"Chemical-genetic Cdk9 inhibition, H2Bub1 epistasis, nascent RNA-seq, and ChIP-seq in fission yeast","pmids":["32496538"],"confidence":"High","gaps":["Direct CDK9 substrate mediating HDAC recruitment not identified","Conservation in human cells not tested here"]},{"year":2020,"claim":"Suggested ASF1B as a stabilizing CDK9 partner that elevates CDK9 protein in cervical cancer.","evidence":"Co-IP, siRNA, overexpression, and xenografts","pmids":["32848135"],"confidence":"Low","gaps":["Stability mechanism not confirmed with ubiquitin/proteasome assays","Single co-IP, single lab"]},{"year":2021,"claim":"Established INTS6-recruited PP2A as the dynamic antagonist of CDK9 on DSIF and the CTD, defining a tunable kinase-phosphatase balance exploitable therapeutically.","evidence":"INTS6 loss-of-function, substrate phosphoproteomics, PP2A activation, and in vivo tumor models","pmids":["34004147"],"confidence":"High","gaps":["Precise recruitment mechanism of PP2A to transcription sites not fully resolved"]},{"year":2021,"claim":"Showed CDK9 and PP2A act as opposing regulators of coupled elongation, termination, and RNA processing, with CDK9 inhibition causing premature termination and loss of SF3B1/polyadenylation factors rescued by PP2A inhibition.","evidence":"CDK9 and PP2A inhibition epistasis, ChIP-seq, metabolic RNA labeling, and chromatin occupancy","pmids":["35980303"],"confidence":"High","gaps":["Direct SF3B1 phosphosite causality not established"]},{"year":2021,"claim":"Defined a ubiquitin-based control of CDK9 abundance via the CSN6-UBR5 axis, with UBR5 promoting CDK9 degradation and CSN6 stabilizing it to drive melanoma.","evidence":"Co-IP, ubiquitination assays, knockdown/overexpression epistasis, and xenografts","pmids":["33483464"],"confidence":"Medium","gaps":["Ubiquitin linkage type and degron not defined","Single lab"]},{"year":2023,"claim":"Showed NELF-dependent pausing creates a strict requirement for CDK9 activity in pause release, explaining why CDK9 inhibition shuts down only NELF-paused genes.","evidence":"NELF depletion with chemical-genetic Cdk9 inhibition and nascent RNA-seq in Drosophila cells","pmids":["37179384"],"confidence":"High","gaps":["Molecular basis of the NELF-imposed checkpoint not fully resolved"]},{"year":2023,"claim":"Identified the L156F kinase-domain mutation as a resistance mechanism to both ATP-competitive CDK9 inhibitors and PROTAC degraders via steric hindrance and altered stability.","evidence":"Acquired-resistance line, CRISPR knock-in, kinase and thermal shift assays","pmids":["37719386"],"confidence":"Medium","gaps":["Clinical prevalence of L156F not established","Single lab"]},{"year":2023,"claim":"Showed OTUD1 deubiquitinase activates CDK9 by K63-linked deubiquitination (via Cys320), driving inflammatory and fibrotic responses in kidney epithelium.","evidence":"Co-IP, deubiquitination assay with catalytic mutant, Otud1 knockout mice, and inhibitor treatment","pmids":["38110583"],"confidence":"Medium","gaps":["How K63 deubiquitination mechanistically activates CDK9 kinase not defined","Single lab"]},{"year":null,"claim":"How the diverse non-canonical CDK9 complexes (cyclin K, CTORC, REV-ERBα) are partitioned from P-TEFb and coordinated in vivo, and which post-translational and ubiquitin signals dominate in physiological versus disease contexts, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Mechanism selecting cyclin/scaffold partner for each CDK9 function unknown","Integration of acetylation, SUMOylation, and ubiquitination control in a single cell not established","Direct structural basis for substrate switching not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,11,13,22]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,14,30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,14,31]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[1,32]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,5,9]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[5,9]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[9,10]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[12,18,29]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,8,14,31]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[23,27,30]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[12,29]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[18,24]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,19]}],"complexes":["P-TEFb (CDK9-cyclin T)","CDK9-cyclin K","7SK snRNP","CTORC1/CTORC2 (CDK9-mLST8)"],"partners":["CCNT1","HEXIM1","SIRT7","TRIM28","INTS6","UBR5","OTUD1","BRCA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50750","full_name":"Cyclin-dependent kinase 9","aliases":["C-2K","Cell division cycle 2-like protein kinase 4","Cell division protein kinase 9","Serine/threonine-protein kinase PITALRE","Tat-associated kinase complex catalytic subunit"],"length_aa":372,"mass_kda":42.8,"function":"Protein kinase involved in the regulation of transcription (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094, PubMed:29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:16427012, PubMed:20930849, PubMed:28426094, PubMed:30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed:16109377, PubMed:20930849, PubMed:28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed:10912001, PubMed:11112772, PubMed:12037670, PubMed:16427012, PubMed:20081228, PubMed:20980437, PubMed:21127351, PubMed:9857195). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed:17956865, PubMed:18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed:10393184, PubMed:11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed:15564463, PubMed:19575011, PubMed:19844166, PubMed:28539972). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed:15564463, PubMed:19575011, PubMed:19844166). Also catalyzes phosphorylation of histone H1.4 (H1-4) at Ser-187' (H1.4S187Ph), a modification associated with transcription activation (PubMed:28539972). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed:20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed:20493174). Promotes cardiac myocyte enlargement (PubMed:20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed:21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed:10912001, PubMed:11112772, PubMed:9857195). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed:12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed:29335245)","subcellular_location":"Nucleus; Cytoplasm; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/P50750/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CDK9","classification":"Common Essential","n_dependent_lines":1199,"n_total_lines":1208,"dependency_fraction":0.9925496688741722},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000136807","cell_line_id":"CID001152","localizations":[{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"CDK12","stoichiometry":10.0},{"gene":"CDK13","stoichiometry":10.0},{"gene":"CCNT1","stoichiometry":10.0},{"gene":"HEXIM1","stoichiometry":10.0},{"gene":"MEPCE","stoichiometry":10.0},{"gene":"LARP7","stoichiometry":10.0},{"gene":"CDC37","stoichiometry":4.0},{"gene":"FKBP5","stoichiometry":4.0},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"CCNT2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001152","total_profiled":1310},"omim":[{"mim_id":"615695","title":"HEXAMETHYLENE BIS ACETAMIDE-INDUCIBLE PROTEIN 2; HEXIM2","url":"https://www.omim.org/entry/615695"},{"mim_id":"611478","title":"METHYLPHOSPHATE CAPPING ENZYME; MEPCE","url":"https://www.omim.org/entry/611478"},{"mim_id":"610252","title":"MICRO RNA 1-2; MIR1-2","url":"https://www.omim.org/entry/610252"},{"mim_id":"609326","title":"MICRO RNA 1-1; MIR1-1","url":"https://www.omim.org/entry/609326"},{"mim_id":"608749","title":"BROMODOMAIN-CONTAINING PROTEIN 4; BRD4","url":"https://www.omim.org/entry/608749"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytoplasmic bodies","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDK9"},"hgnc":{"alias_symbol":["PITALRE","C-2k","TAK"],"prev_symbol":["CDC2L4"]},"alphafold":{"accession":"P50750","domains":[{"cath_id":"3.30.200.20","chopping":"15-103","consensus_level":"high","plddt":89.1928,"start":15,"end":103},{"cath_id":"1.10.510.10","chopping":"108-338","consensus_level":"high","plddt":94.5981,"start":108,"end":338}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50750","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50750-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50750-F1-predicted_aligned_error_v6.png","plddt_mean":86.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDK9","jax_strain_url":"https://www.jax.org/strain/search?query=CDK9"},"sequence":{"accession":"P50750","fasta_url":"https://rest.uniprot.org/uniprotkb/P50750.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50750/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50750"}},"corpus_meta":[{"pmid":"29251720","id":"PMC_29251720","title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.","date":"2017","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/29251720","citation_count":421,"is_preprint":false},{"pmid":"28673542","id":"PMC_28673542","title":"BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28673542","citation_count":394,"is_preprint":false},{"pmid":"8170997","id":"PMC_8170997","title":"PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8170997","citation_count":222,"is_preprint":false},{"pmid":"12832472","id":"PMC_12832472","title":"MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12832472","citation_count":211,"is_preprint":false},{"pmid":"28994650","id":"PMC_28994650","title":"CDK9-dependent RNA polymerase II pausing controls transcription initiation.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28994650","citation_count":189,"is_preprint":false},{"pmid":"30454645","id":"PMC_30454645","title":"Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/30454645","citation_count":184,"is_preprint":false},{"pmid":"30227759","id":"PMC_30227759","title":"CDK9: a signaling hub for transcriptional control.","date":"2018","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/30227759","citation_count":162,"is_preprint":false},{"pmid":"34004147","id":"PMC_34004147","title":"The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/34004147","citation_count":155,"is_preprint":false},{"pmid":"26766294","id":"PMC_26766294","title":"Overview of CDK9 as a target in cancer research.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26766294","citation_count":151,"is_preprint":false},{"pmid":"29471852","id":"PMC_29471852","title":"CDK9 inhibitors in acute myeloid leukemia.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29471852","citation_count":125,"is_preprint":false},{"pmid":"7882308","id":"PMC_7882308","title":"Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7882308","citation_count":125,"is_preprint":false},{"pmid":"9557739","id":"PMC_9557739","title":"PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.","date":"1998","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9557739","citation_count":117,"is_preprint":false},{"pmid":"11282025","id":"PMC_11282025","title":"The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions.","date":"2001","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11282025","citation_count":116,"is_preprint":false},{"pmid":"20980437","id":"PMC_20980437","title":"CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20980437","citation_count":114,"is_preprint":false},{"pmid":"34062779","id":"PMC_34062779","title":"Targeting CDK9 for Anti-Cancer Therapeutics.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34062779","citation_count":109,"is_preprint":false},{"pmid":"28722178","id":"PMC_28722178","title":"CDK9: A key player in cancer and other diseases.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28722178","citation_count":99,"is_preprint":false},{"pmid":"15286705","id":"PMC_15286705","title":"Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15286705","citation_count":98,"is_preprint":false},{"pmid":"30652970","id":"PMC_30652970","title":"TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30652970","citation_count":95,"is_preprint":false},{"pmid":"32866383","id":"PMC_32866383","title":"Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32866383","citation_count":81,"is_preprint":false},{"pmid":"12861003","id":"PMC_12861003","title":"CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12861003","citation_count":77,"is_preprint":false},{"pmid":"18473913","id":"PMC_18473913","title":"CDK9 a potential target for drug development.","date":"2008","source":"Medicinal chemistry (Shariqah (United Arab Emirates))","url":"https://pubmed.ncbi.nlm.nih.gov/18473913","citation_count":72,"is_preprint":false},{"pmid":"34146121","id":"PMC_34146121","title":"CDK9 keeps RNA polymerase II on track.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/34146121","citation_count":70,"is_preprint":false},{"pmid":"15452830","id":"PMC_15452830","title":"Differential localization and expression of the Cdk9 42k and 55k isoforms.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15452830","citation_count":64,"is_preprint":false},{"pmid":"17485025","id":"PMC_17485025","title":"TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.","date":"2007","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/17485025","citation_count":59,"is_preprint":false},{"pmid":"12432243","id":"PMC_12432243","title":"CDK9: from basal transcription to cancer and AIDS.","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12432243","citation_count":57,"is_preprint":false},{"pmid":"27833949","id":"PMC_27833949","title":"The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.","date":"2017","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/27833949","citation_count":56,"is_preprint":false},{"pmid":"15049426","id":"PMC_15049426","title":"Regulation of TAK/P-TEFb in CD4+ T lymphocytes and macrophages.","date":"2003","source":"Current HIV research","url":"https://pubmed.ncbi.nlm.nih.gov/15049426","citation_count":56,"is_preprint":false},{"pmid":"27582311","id":"PMC_27582311","title":"Targeting CDK9: a promising therapeutic opportunity in prostate cancer.","date":"2016","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27582311","citation_count":55,"is_preprint":false},{"pmid":"15780980","id":"PMC_15780980","title":"Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15780980","citation_count":55,"is_preprint":false},{"pmid":"32848135","id":"PMC_32848135","title":"ASF1B promotes cervical cancer progression through stabilization of CDK9.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32848135","citation_count":55,"is_preprint":false},{"pmid":"10092203","id":"PMC_10092203","title":"CDK9 (PITALRE): a multifunctional cdc2-related kinase.","date":"1998","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10092203","citation_count":52,"is_preprint":false},{"pmid":"8870681","id":"PMC_8870681","title":"The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8870681","citation_count":52,"is_preprint":false},{"pmid":"31131319","id":"PMC_31131319","title":"Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31131319","citation_count":52,"is_preprint":false},{"pmid":"34538051","id":"PMC_34538051","title":"Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34538051","citation_count":52,"is_preprint":false},{"pmid":"28426094","id":"PMC_28426094","title":"SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28426094","citation_count":51,"is_preprint":false},{"pmid":"21200140","id":"PMC_21200140","title":"A role for CDK9-cyclin K in maintaining genome integrity.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21200140","citation_count":50,"is_preprint":false},{"pmid":"32859893","id":"PMC_32859893","title":"Distinct Cdk9-phosphatase switches act at the beginning and end of elongation by RNA polymerase II.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32859893","citation_count":49,"is_preprint":false},{"pmid":"9766517","id":"PMC_9766517","title":"Cloning of murine CDK9/PITALRE and its tissue-specific expression in development.","date":"1998","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9766517","citation_count":48,"is_preprint":false},{"pmid":"31398271","id":"PMC_31398271","title":"Targeting CDK9 for treatment of colorectal cancer.","date":"2019","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31398271","citation_count":43,"is_preprint":false},{"pmid":"37272701","id":"PMC_37272701","title":"Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.","date":"2023","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37272701","citation_count":42,"is_preprint":false},{"pmid":"19757441","id":"PMC_19757441","title":"Pharmacological targeting of CDK9 in cardiac hypertrophy.","date":"2010","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19757441","citation_count":40,"is_preprint":false},{"pmid":"16720337","id":"PMC_16720337","title":"Mechanisms controlling CDK9 activity.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16720337","citation_count":38,"is_preprint":false},{"pmid":"30587525","id":"PMC_30587525","title":"Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30587525","citation_count":37,"is_preprint":false},{"pmid":"24524087","id":"PMC_24524087","title":"Regulation of CDK9 activity by phosphorylation and dephosphorylation.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24524087","citation_count":36,"is_preprint":false},{"pmid":"31257635","id":"PMC_31257635","title":"Transient induction of Cdk9 in the early stage of differentiation is critical for myogenesis.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31257635","citation_count":36,"is_preprint":false},{"pmid":"9258347","id":"PMC_9258347","title":"CDC2-related kinase PITALRE phosphorylates pRb exclusively on serine and is widely expressed in human tissues.","date":"1997","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9258347","citation_count":35,"is_preprint":false},{"pmid":"35980303","id":"PMC_35980303","title":"CDK9 and PP2A regulate RNA polymerase II transcription termination and coupled RNA maturation.","date":"2022","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/35980303","citation_count":34,"is_preprint":false},{"pmid":"33712455","id":"PMC_33712455","title":"LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33712455","citation_count":34,"is_preprint":false},{"pmid":"29588524","id":"PMC_29588524","title":"SUMO suppresses and MYC amplifies transcription globally by regulating CDK9 sumoylation.","date":"2018","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29588524","citation_count":34,"is_preprint":false},{"pmid":"30076726","id":"PMC_30076726","title":"MALAT1 induces osteosarcoma progression by targeting miR-206/CDK9 axis.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30076726","citation_count":32,"is_preprint":false},{"pmid":"30362418","id":"PMC_30362418","title":"CDK9 as an Appealing Target for Therapeutic Interventions.","date":"2019","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/30362418","citation_count":31,"is_preprint":false},{"pmid":"29063678","id":"PMC_29063678","title":"Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.","date":"2018","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29063678","citation_count":31,"is_preprint":false},{"pmid":"36998071","id":"PMC_36998071","title":"CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36998071","citation_count":30,"is_preprint":false},{"pmid":"36809797","id":"PMC_36809797","title":"TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36809797","citation_count":29,"is_preprint":false},{"pmid":"27511630","id":"PMC_27511630","title":"Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27511630","citation_count":29,"is_preprint":false},{"pmid":"12063565","id":"PMC_12063565","title":"Role of cyclinT/Cdk9 complex in basal and regulated transcription (review).","date":"2002","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12063565","citation_count":28,"is_preprint":false},{"pmid":"18655042","id":"PMC_18655042","title":"RNA-driven cyclin-dependent kinase regulation: when CDK9/cyclin T subunits of P-TEFb meet their ribonucleoprotein partners.","date":"2008","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/18655042","citation_count":27,"is_preprint":false},{"pmid":"28608935","id":"PMC_28608935","title":"CDK9 Regulates Apoptosis of Myoblast Cells by Modulation of microRNA-1 Expression.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28608935","citation_count":27,"is_preprint":false},{"pmid":"35092513","id":"PMC_35092513","title":"CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.","date":"2022","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35092513","citation_count":26,"is_preprint":false},{"pmid":"32496538","id":"PMC_32496538","title":"Cdk9 and H2Bub1 signal to Clr6-CII/Rpd3S to suppress aberrant antisense transcription.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/32496538","citation_count":26,"is_preprint":false},{"pmid":"31866490","id":"PMC_31866490","title":"CDK9 inhibitors reactivate p53 by downregulating iASPP.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31866490","citation_count":25,"is_preprint":false},{"pmid":"9003389","id":"PMC_9003389","title":"Phosphorylation site specificity of the CDC2-related kinase PITALRE.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9003389","citation_count":25,"is_preprint":false},{"pmid":"33483464","id":"PMC_33483464","title":"CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33483464","citation_count":25,"is_preprint":false},{"pmid":"35614071","id":"PMC_35614071","title":"Molecular mechanism of the wake-promoting agent TAK-925.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35614071","citation_count":24,"is_preprint":false},{"pmid":"37179384","id":"PMC_37179384","title":"The NELF pausing checkpoint mediates the functional divergence of Cdk9.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37179384","citation_count":24,"is_preprint":false},{"pmid":"31758083","id":"PMC_31758083","title":"Transcription modulation by CDK9 regulates inflammatory genes and RIPK3-MLKL-mediated necroptosis in periodontitis progression.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31758083","citation_count":24,"is_preprint":false},{"pmid":"35628286","id":"PMC_35628286","title":"Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628286","citation_count":24,"is_preprint":false},{"pmid":"32934219","id":"PMC_32934219","title":"CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32934219","citation_count":24,"is_preprint":false},{"pmid":"32901849","id":"PMC_32901849","title":"Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32901849","citation_count":23,"is_preprint":false},{"pmid":"37719386","id":"PMC_37719386","title":"Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/37719386","citation_count":22,"is_preprint":false},{"pmid":"32331282","id":"PMC_32331282","title":"RSV Reprograms the CDK9•BRD4 Chromatin Remodeling Complex to Couple Innate Inflammation to Airway Remodeling.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/32331282","citation_count":22,"is_preprint":false},{"pmid":"35814933","id":"PMC_35814933","title":"CDK9 inhibitors in cancer research.","date":"2022","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35814933","citation_count":21,"is_preprint":false},{"pmid":"38808256","id":"PMC_38808256","title":"Structure-guided design and cloning of peptide inhibitors targeting CDK9/cyclin T1 protein-protein interaction.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38808256","citation_count":21,"is_preprint":false},{"pmid":"28278048","id":"PMC_28278048","title":"BRCA1 recruitment to damaged DNA sites is dependent on CDK9.","date":"2017","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/28278048","citation_count":21,"is_preprint":false},{"pmid":"14749500","id":"PMC_14749500","title":"Phosphorylation of RNA polymerase II in cardiac hypertrophy: cell enlargement signals converge on cyclin T/Cdk9.","date":"2004","source":"Recent progress in hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/14749500","citation_count":20,"is_preprint":false},{"pmid":"31857848","id":"PMC_31857848","title":"Analog-sensitive cell line identifies cellular substrates of CDK9.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31857848","citation_count":20,"is_preprint":false},{"pmid":"15675611","id":"PMC_15675611","title":"TAK-375 Takeda.","date":"2005","source":"Current opinion in investigational drugs (London, England : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/15675611","citation_count":19,"is_preprint":false},{"pmid":"35884401","id":"PMC_35884401","title":"Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35884401","citation_count":19,"is_preprint":false},{"pmid":"31892980","id":"PMC_31892980","title":"Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31892980","citation_count":19,"is_preprint":false},{"pmid":"34207158","id":"PMC_34207158","title":"Targeting CDK9 for the Treatment of Glioblastoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34207158","citation_count":18,"is_preprint":false},{"pmid":"38001268","id":"PMC_38001268","title":"Selective inhibition of CDK9 in triple negative breast cancer.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38001268","citation_count":18,"is_preprint":false},{"pmid":"36087428","id":"PMC_36087428","title":"Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia.","date":"2022","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36087428","citation_count":17,"is_preprint":false},{"pmid":"30132679","id":"PMC_30132679","title":"Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.","date":"2018","source":"The American journal of managed care","url":"https://pubmed.ncbi.nlm.nih.gov/30132679","citation_count":17,"is_preprint":false},{"pmid":"38564299","id":"PMC_38564299","title":"Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38564299","citation_count":16,"is_preprint":false},{"pmid":"23603988","id":"PMC_23603988","title":"Cdk9 phosphorylates Pirh2 protein and prevents degradation of p53 protein.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23603988","citation_count":16,"is_preprint":false},{"pmid":"34592899","id":"PMC_34592899","title":"Inhibition of CDK9 activity compromises global splicing in prostate cancer cells.","date":"2021","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/34592899","citation_count":16,"is_preprint":false},{"pmid":"33117517","id":"PMC_33117517","title":"Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia.","date":"2020","source":"Therapeutic advances in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33117517","citation_count":16,"is_preprint":false},{"pmid":"31307784","id":"PMC_31307784","title":"CDK9 attenuation exerts protective effects on catabolism and hypertrophy in chondrocytes and ameliorates osteoarthritis development.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31307784","citation_count":16,"is_preprint":false},{"pmid":"28434229","id":"PMC_28434229","title":"Cell Cycle-Dependent Kinase Cdk9 Is a Postexposure Drug Target against Human Adenoviruses.","date":"2017","source":"ACS infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28434229","citation_count":15,"is_preprint":false},{"pmid":"36854448","id":"PMC_36854448","title":"Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition.","date":"2023","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36854448","citation_count":15,"is_preprint":false},{"pmid":"31384313","id":"PMC_31384313","title":"Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.","date":"2019","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31384313","citation_count":15,"is_preprint":false},{"pmid":"37551745","id":"PMC_37551745","title":"CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.","date":"2024","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37551745","citation_count":14,"is_preprint":false},{"pmid":"38110583","id":"PMC_38110583","title":"OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells.","date":"2023","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38110583","citation_count":13,"is_preprint":false},{"pmid":"31005255","id":"PMC_31005255","title":"CDK9 modulates circadian clock by attenuating REV-ERBα activity.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31005255","citation_count":13,"is_preprint":false},{"pmid":"35121112","id":"PMC_35121112","title":"The establishment of CDK9/RNA PolII/H3K4me3/DNA methylation feedback promotes HOTAIR expression by RNA elongation enhancement in cancer.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35121112","citation_count":13,"is_preprint":false},{"pmid":"32048975","id":"PMC_32048975","title":"CDK9: Therapeutic Perspective in HCC Therapy.","date":"2020","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/32048975","citation_count":12,"is_preprint":false},{"pmid":"40487652","id":"PMC_40487652","title":"First ATG101-recruiting small molecule degrader for selective CDK9 degradation via autophagy-lysosome pathway.","date":"2025","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/40487652","citation_count":12,"is_preprint":false},{"pmid":"31934590","id":"PMC_31934590","title":"TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway.","date":"2019","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/31934590","citation_count":12,"is_preprint":false},{"pmid":"33631230","id":"PMC_33631230","title":"CDK9 inhibition improves diabetic nephropathy by reducing inflammation in the kidneys.","date":"2021","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33631230","citation_count":12,"is_preprint":false},{"pmid":"36207468","id":"PMC_36207468","title":"Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody.","date":"2022","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36207468","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45466,"output_tokens":8495,"usd":0.131911,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18357,"output_tokens":8046,"usd":0.146468,"stage2_stop_reason":"end_turn"},"total_usd":0.278379,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"PITALRE (CDK9) is a nuclear CDC2-related serine/threonine protein kinase that phosphorylates the retinoblastoma protein (pRb) in vitro but cannot phosphorylate histone H1, indicating a substrate specificity distinct from CDC2. It associates with three cellular polypeptides of 80, 95, and 155 kDa and localizes primarily to the nucleus.\",\n      \"method\": \"Immunoprecipitation-associated in vitro kinase assay, immunofluorescence, cDNA cloning\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with clear substrate discrimination, replicated across subsequent studies, foundational paper\",\n      \"pmids\": [\"8170997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PITALRE (CDK9) is the catalytic subunit responsible for kinase activity in its multimeric complexes, demonstrated using a catalytically inactive mutant. Monomeric CDK9 is active in vitro but PITALRE in multimeric complexes exhibits several-fold higher activity, suggesting regulatory proteins modulate its activity and/or substrate recognition.\",\n      \"method\": \"Dominant-negative catalytic mutant overexpression, in vitro kinase assay, protein complex characterization\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — catalytic mutant reconstitution experiment directly establishing CDK9 as the catalytic subunit\",\n      \"pmids\": [\"8870681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PITALRE (CDK9) is a Ser/Thr proline-directed kinase. It phosphorylates myelin basic protein (MBP) on Ser-162 (a proline-directed residue) and Thr-97, with substrate site specificity distinguishable from CDC2 and CDK2.\",\n      \"method\": \"In vitro kinase assay with phosphopeptide mapping and phosphoamino acid analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro phosphorylation site mapping with multiple independent antibodies confirming identical activities\",\n      \"pmids\": [\"9003389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PITALRE (CDK9)-associated kinase activity phosphorylates pRb exclusively on serine residues at sites similar to those phosphorylated by CDC2 kinase in vitro.\",\n      \"method\": \"In vitro kinase assay with phosphoamino acid analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — single in vitro experiment confirming serine-only phosphorylation of pRb, single lab\",\n      \"pmids\": [\"9258347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PITALRE (CDK9) is the catalytic subunit of the Tat-associated kinase (TAK) and is required for HIV-1 Tat transactivation in vivo. A catalytic mutant (D167N) more efficiently squelches Tat transactivation than wild-type CDK9. Artificial tethering of PITALRE to a nascent RNA element, in the absence of Tat, activates HIV-1 LTR expression.\",\n      \"method\": \"Transient overexpression, catalytic mutant analysis, artificial RNA-tethering assay, HIV-1 LTR reporter assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal experiments (dominant-negative, artificial tethering, integrated and transfected reporters) establishing CDK9 as mediator of Tat transactivation\",\n      \"pmids\": [\"9557739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CDK9 and cyclin T1 localize throughout the non-nucleolar nucleoplasm and concentrate at nuclear speckles that are enriched in splicing factors. The pattern is altered by transcription inhibitors. A central region of cyclin T1 mediates speckle accumulation and can recruit CDK9 and HIV Tat to this compartment.\",\n      \"method\": \"High-resolution immunofluorescence microscopy, cyclin T1 deletion mutants, co-expression experiments\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiment with functional domain mapping and pharmacological perturbation, replicated with multiple antibodies and deletion constructs\",\n      \"pmids\": [\"11282025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A novel protein MAQ1 (HEXIM1) associates with the inactive P-TEFb complex in a manner dependent on 7SK snRNA. MAQ1 binds directly to the N-terminal cyclin homology region of cyclin T1 and T2, and this 7SK RNA/MAQ1 association competes with Tat binding to cyclin T1. Transcription inhibition releases both MAQ1 and 7SK RNA from P-TEFb, indicating a dynamic regulatory mechanism for CDK9 activity.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, transcription inhibitor treatment, protein complex characterization\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP plus yeast two-hybrid, identifying binding domain and competitive interaction; replicated across labs\",\n      \"pmids\": [\"12832472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CDK9 protein levels are constitutively expressed throughout the cell cycle and are not regulated by the SCF(SKP2) ubiquitin ligase. Endogenous CDK9 is a stable protein (half-life 4–7 h), while overexpressed CDK9 is rapidly degraded (half-life <1 h). CDK9 kinase activity does not oscillate during the cell cycle.\",\n      \"method\": \"Cell cycle synchronization experiments, cycloheximide chase, SKP2 siRNA knockdown, proteasome inhibitor treatment, Western blot\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (synchronization, knockdown, inhibitors) consistently showing cell cycle-independent expression and activity\",\n      \"pmids\": [\"12861003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CDK9 (as part of P-TEFb) is recruited by STAT3 to the p21waf1 promoter to phosphorylate the CTD of RNA polymerase II at serine 2, enabling transcription elongation. BRG1 is recruited first to remodel chromatin, followed by CDK9 recruitment to drive elongation at the STAT3 target gene.\",\n      \"method\": \"Co-immunoprecipitation, pull-down, chromatin immunoprecipitation (ChIP), Southern blot accessibility assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and Co-IP demonstrate ordered recruitment, single lab with two orthogonal methods\",\n      \"pmids\": [\"15286705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CDK9 has two isoforms, 42k and 55k. Both isoforms phosphorylate the CTD of RNA polymerase II with identical phosphorylation patterns on 144 peptide substrates. CDK9-42k localizes diffusely in the nucleoplasm while CDK9-55k accumulates in the nucleolus. Expression of the 55k isoform is induced upon macrophage differentiation while the 42k isoform predominates in activated lymphocytes.\",\n      \"method\": \"Immunofluorescence, kinase assay with peptide array, immunoblot of primary cells, promoter reporter assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — differential localization established by direct imaging with multiple orthogonal methods including kinase assay and primary cell analysis\",\n      \"pmids\": [\"15452830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The Cdk9(55) isoform is localized to the nucleus and is expressed as the predominant form in primary rat hepatocytes; as cells enter the cell cycle, CDK9(42) expression is induced and becomes the major form while CDK9(55) remains relatively constant. The relative abundance of the two isoforms varies across mouse tissues.\",\n      \"method\": \"Immunofluorescence, Western blot of murine tissues and primary hepatocytes, tetracycline-inducible expression\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization and expression profiling in primary cells and tissues, single lab\",\n      \"pmids\": [\"15780980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CDK9 phosphorylates the androgen receptor (AR) on serine 81 (S81) in vitro in a site-specific manner. CDK9 co-immunoprecipitates with AR. Overexpression of CDK9 with cyclin T increases S81 phosphorylation; CDK9 siRNA knockdown and CDK9 inhibitors reduce hormone-induced S81 phosphorylation. S81 phosphorylation regulates AR promoter selectivity and cell growth.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, mass spectrometry, siRNA knockdown, pharmacological inhibition, reporter assay\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay plus multiple cellular validation approaches (siRNA, OE, inhibitors), single lab with multiple orthogonal methods\",\n      \"pmids\": [\"20980437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CDK9 in complex with cyclin K (not cyclin T) directly functions in maintaining genome integrity in response to replication stress. CDK9-cyclin K (but not CDK9-cyclin T) depletion impairs cell cycle recovery after replication stress, induces spontaneous DNA damage, and CDK9 accumulates on chromatin to limit single-stranded DNA accumulation. CDK9-cyclin K interacts with ATR and DNA damage response proteins.\",\n      \"method\": \"Cyclin-specific siRNA depletion, DNA damage assays, chromatin fractionation, co-immunoprecipitation, cell cycle analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cyclin-specific depletion distinguishes CDK9-cyclin K from CDK9-cyclin T function, multiple orthogonal readouts\",\n      \"pmids\": [\"21200140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDK9 physically interacts with Pirh2 and phosphorylates it on Ser-211 and Thr-217, rendering Pirh2 inactive and contributing to p53 stabilization. CDK9 also promotes phosphorylation of Mdm2 on Ser-395, preventing Mdm2-mediated p53 degradation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, Western blot, site-directed mutagenesis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay and co-IP, single lab, no independent replication\",\n      \"pmids\": [\"23603988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK9 activity decreases the pause duration of promoter-proximally paused RNA Pol II and increases productive initiation frequency, demonstrating that CDK9 stimulates release of paused polymerase and activates transcription by increasing the number of transcribing polymerases and the amount of mRNA synthesized. CDK9 activity is also associated with long-range chromatin interactions.\",\n      \"method\": \"Chemical-genetic CDK9 inhibition in engineered human cells combined with multi-omics (transient transcriptome sequencing, 4sU-seq, Hi-C)\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-omics approach with specific rapid CDK9 inhibition in engineered cells, quantitative mechanistic dissection\",\n      \"pmids\": [\"28994650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SIRT7 deacetylates CDK9 at lysine 48, counteracting GCN5-mediated acetylation, which activates CDK9 kinase activity to phosphorylate Pol II CTD serine 2 and promote transcription elongation. SIRT7 also promotes release of P-TEFb from the inactive 7SK snRNP complex.\",\n      \"method\": \"Proteomic identification of SIRT7 substrates, co-immunoprecipitation, in vitro deacetylation assay, CTD phosphorylation assay, SIRT7 depletion\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro deacetylation assay combined with in-cell validation and identification of the modifying enzymes (SIRT7 and GCN5), multiple methods\",\n      \"pmids\": [\"28426094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"THAL-SNS-032, a CDK9 degrader (PROTAC with thalidomide moiety recruiting Cereblon E3 ligase), selectively degrades CDK9 without affecting other SNS-032 targets, demonstrating that CDK9 degradation induces distinct and prolonged pharmacological effects (including irreversible apoptosis after washout) compared with CDK9 kinase inhibition alone.\",\n      \"method\": \"PROTAC-mediated targeted protein degradation, washout experiments, transcriptome profiling, cell viability assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — selective degrader vs. inhibitor comparison with transcriptome profiling and functional assays, multiple orthogonal methods\",\n      \"pmids\": [\"29251720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SUMO suppresses global transcription by promoting sumoylation of CDK9, which blocks CDK9 interaction with Cyclin T1 and thus prevents formation of the active P-TEFb complex. MYC antagonizes CDK9 sumoylation to amplify global transcription. A sumoylation-resistant CDK9 mutant confirms that CDK9 sumoylation inhibits global transcription.\",\n      \"method\": \"SUMO-MS, SUMOylation assays, co-immunoprecipitation, sumoylation-resistant mutant, transcription profiling\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro SUMOylation assays, mutagenesis with sumoylation-resistant mutant, and transcription profiling in same study\",\n      \"pmids\": [\"29588524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK9 inhibition dephosphorylates the SWI/SNF protein BRG1 and contributes to reactivation of epigenetically silenced genes including tumor suppressor genes in cancer cells. CDK9 is essential for maintaining gene silencing at heterochromatic loci in addition to its role in transcription elongation.\",\n      \"method\": \"Live cell drug screen with genetic confirmation, siRNA knockdown, pharmacological inhibition, gene expression analysis, ChIP\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological validation with multiple cancer models, identification of BRG1 as substrate\",\n      \"pmids\": [\"30454645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRIM28 SUMOylates CDK9 at lysines 44, 56, and 68 (using SUMO4), which inhibits CDK9 kinase activity and/or prevents P-TEFb assembly by blocking CDK9-Cyclin T1 interaction, thereby suppressing HIV-1 transcription and contributing to viral latency.\",\n      \"method\": \"Global site-specific SUMO-MS, serial SUMOylation assays, kinase activity assays, co-immunoprecipitation, site-directed mutagenesis of SUMOylation sites\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mass spectrometry identification of SUMOylation sites confirmed by serial biochemical assays and mutagenesis, mechanistic consequence on P-TEFb assembly demonstrated\",\n      \"pmids\": [\"30652970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK9 forms novel complexes (CTORC1 and CTORC2) with mTOR scaffold protein mLST8. In the nucleus, CDK9-RAPTOR-mLST8 (CTORC1) promotes transcription of leukemogenic genes. In the cytoplasm, CDK9-RICTOR-SIN1-mLST8 (CTORC2) controls mRNA translation through phosphorylation of LARP1 and rpS6.\",\n      \"method\": \"Proteomics/mass spectrometry of mTOR complex interactors, co-immunoprecipitation, subcellular fractionation, phosphorylation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic identification with co-IP validation, single lab, novel finding not yet independently replicated\",\n      \"pmids\": [\"30587525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK9 modulates the circadian clock by physically associating with REV-ERBα and attenuating its binding to the RORE element in the Bmal1 promoter. CDK9 knockdown in the anterior hypothalamus (SCN region) in mice alters respiratory exchange ratio, daily activity, and circadian period.\",\n      \"method\": \"siRNA screen, CDK9 siRNA knockdown, co-immunoprecipitation, in vivo hypothalamic knockdown, circadian phenotype measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of CDK9-REV-ERBα with in vivo knockdown phenotype, single lab\",\n      \"pmids\": [\"31005255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK9 (P-TEFb) phosphorylates PP1 and PP4 phosphatase complexes (inhibitory phosphorylation), creating two distinct kinase-phosphatase switches: PP4 governs pause release at the 5' end of genes by dephosphorylating Spt5-Ser666 and the Spt5 CTR, while PP1 governs the elongation-termination transition at gene 3' ends by dephosphorylating the Spt5 CTR. Depletion of PP4 complex subunits redistributes paused Pol II into gene bodies.\",\n      \"method\": \"Kinase-phosphatase depletion experiments, phosphoproteomics, ChIP-seq, in vivo Spt5 phosphorylation analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (depletion, phosphoproteomics, ChIP-seq) identifying two distinct substrate-specific kinase-phosphatase switches\",\n      \"pmids\": [\"32859893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK9 inhibition globally impairs splicing of thousands of mRNAs in prostate cancer cells, with no coordinated response between alternative splicing and the transcriptome. CDK9 inhibition causes loss of androgen receptor (AR) and AR-v7 splice variant expression, sensitizing CRPC cells to androgen deprivation.\",\n      \"method\": \"RNA-seq, splicing analysis, CDK9 inhibitor treatment, AR splice variant analysis, androgen deprivation assays\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptome-wide splicing analysis with CDK9-targeted inhibition in multiple prostate cancer cell lines, single lab\",\n      \"pmids\": [\"34592899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cdk9 inhibition or H2B mono-ubiquitination (H2Bub1) loss independently induces intragenic antisense transcription in fission yeast, affecting largely distinct gene subsets. Combined ablation de-represses antisense transcription of over half the genome. CDK9-dependence correlates with high H2Bub1 occupancy. Combined perturbation impairs Clr6-CII (HDAC) recruitment and increases histone acetylation in coding regions.\",\n      \"method\": \"Chemical-genetic Cdk9 inhibition, H2Bub1 loss epistasis, genome-wide nascent RNA sequencing, ChIP-seq, genetic interaction analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide epistasis between Cdk9 and H2Bub1 with mechanistic link to Clr6-CII HDAC recruitment, multiple orthogonal methods\",\n      \"pmids\": [\"32496538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASF1B forms stable complexes with CDK9 and positively regulates CDK9 protein stability, functioning as an oncogenic stabilizer of CDK9 in cervical cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, xenograft models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP establishing complex, stability mechanism not biochemically confirmed with ubiquitin/proteasome assays, single lab\",\n      \"pmids\": [\"32848135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A PP2A complex recruited to transcription sites by Integrator complex subunit INTS6 dynamically antagonizes CDK9-mediated phosphorylation of key substrates including DSIF and RNAPII-CTD. Loss of INTS6 results in resistance to CDK9 inhibition and amplification of acute oncogenic transcriptional responses. Pharmacological PP2A activation synergizes with CDK9 inhibition.\",\n      \"method\": \"INTS6 loss-of-function, phosphoproteomic analysis of CDK9 substrates, pharmacological PP2A activation, cell viability assays, in vivo tumor models\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate-specific phosphoproteomics with genetic loss-of-function and pharmacological validation, in vivo confirmation\",\n      \"pmids\": [\"34004147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK9 inhibits CDK9 substrates including SF3B1 (splicing factor), and inhibition causes loss of SF3B1 and polyadenylation factors from chromatin. CDK9 inhibition also causes premature transcription termination across the last exon and loss of polyadenylation of nascent transcripts. PP2A inhibition rescues premature termination caused by CDK9 inhibition, placing CDK9 and PP2A as opposing regulators of coupled transcription elongation, termination, and RNA processing.\",\n      \"method\": \"CDK9 inhibition and PP2A inhibition, ChIP-seq, metabolic RNA labeling, polyadenylation factor chromatin occupancy assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistatic rescue experiment (PP2A inhibition rescuing CDK9 inhibition phenotypes) plus direct chromatin occupancy measurements, multiple orthogonal methods\",\n      \"pmids\": [\"35980303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSN6 stabilizes CDK9 protein by reducing CDK9 ubiquitination levels. The E3 ligase UBR5 is negatively regulated by CSN6 and promotes ubiquitination and degradation of CDK9. The CSN6-UBR5-CDK9 axis promotes melanoma proliferation and metastasis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, overexpression, xenograft models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay with genetic epistasis (UBR5 KD rescuing CSN6 KD), identification of E3 ligase, single lab\",\n      \"pmids\": [\"33483464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRCA1 recruitment to DNA damage sites (ionizing radiation-induced foci) is dependent on CDK9. CDK9 interacts with endogenous BRCA1 and BARD1 through RING finger and BRCT domains, forms IRIF at DNA damage sites, and co-localizes with BRCA1. CDK9-deficient cells show altered γ-H2AX dynamics, reduced HR efficiency, and failure to form BRCA1 and RAD51 IRIF.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence microscopy of IRIF, CDK9 siRNA knockdown, HR/NHEJ repair assays, genotoxic sensitivity assays\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP for interaction plus functional DNA repair assays, multiple readouts, single lab\",\n      \"pmids\": [\"28278048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Using analog-sensitive CDK9 combined with quantitative phosphoproteomics, 1,102 phosphosites and 120 potential cellular CDK9 substrates were identified. A substantial number of CDK9 substrates are splicing factors, establishing CDK9's role in transcription-coupled splicing. Cellular context fundamentally impacts CDK9 substrate selection compared to in vitro data.\",\n      \"method\": \"Analog-sensitive kinase technology, quantitative phosphoproteomics, chemical-genetic inhibition\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — analog-sensitive kinase combined with quantitative mass spectrometry, direct identification of cellular CDK9 substrates at proteome scale\",\n      \"pmids\": [\"31857848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NELF-mediated promoter-proximal pausing establishes a strict checkpoint requiring Cdk9 kinase activity for pause release into productive elongation. In NELF-depleted cells, Cdk9 inhibition does not efficiently shut down gene transcription but instead allows defective, non-productive transcription to continue. Only NELF-dependent pausing creates this strict Cdk9 requirement.\",\n      \"method\": \"NELF depletion in Drosophila cells, chemical-genetic Cdk9 inhibition, nascent RNA sequencing, epistasis analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (NELF depletion) combined with specific chemical-genetic Cdk9 inhibition plus genome-wide transcription readout; mechanistically rigorous\",\n      \"pmids\": [\"37179384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The CDK9 kinase domain mutation L156F confers resistance to CDK9 inhibitors including both ATP-competitive inhibitors and PROTAC degraders by causing steric hindrance to inhibitor binding and altering CDK9 thermal stability and catalytic activity.\",\n      \"method\": \"Acquired resistance cell line, genomic sequencing, CRISPR/Cas9 knock-in, kinase activity assays, thermal shift assay\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knock-in of resistance mutation with biochemical characterization of the mechanism, single lab\",\n      \"pmids\": [\"37719386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"OTUD1 deubiquitinase binds CDK9 and catalyzes K63-linked deubiquitination on CDK9 (with Cys320 of OTUD1 being critical), promoting CDK9 phosphorylation and activation to induce inflammatory responses and fibrosis in kidney epithelial cells.\",\n      \"method\": \"Co-immunoprecipitation, deubiquitination assay with OTUD1 catalytic mutant, Otud1 knockout mice, CDK9 inhibitor treatment, phosphorylation assays\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deubiquitination assay with catalytic mutant identifying specific linkage type, in vivo Otud1 KO validation, single lab\",\n      \"pmids\": [\"38110583\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDK9, the catalytic subunit of P-TEFb (complexed with cyclin T1, T2, or K), is a nuclear serine/threonine proline-directed kinase that phosphorylates the Ser2 residue of the RNAPII CTD heptad repeat and the negative elongation factors DSIF/Spt5 and NELF to release promoter-proximally paused RNA polymerase II into productive transcription elongation; its activity is regulated by dynamic inhibitory sequestration in the 7SK snRNP complex (through HEXIM1/MAQ1 and 7SK RNA binding cyclin T), by post-translational modifications including phosphorylation, acetylation by GCN5 (inactivating) and deacetylation by SIRT7 (activating), and SUMOylation by TRIM28 (blocking Cyclin T1 interaction); CDK9 is opposed by PP2A (recruited via INTS6) and PP4 phosphatase complexes that dephosphorylate CDK9 substrates to govern pause release and elongation-termination transitions, respectively; additionally, CDK9-cyclin K (distinct from the P-TEFb cyclin T complexes) functions in genome integrity maintenance in response to replication stress by interacting with ATR; CDK9 also phosphorylates non-transcription substrates including the androgen receptor (Ser81), Pirh2 (Ser211/Thr217), and splicing factors, and its protein stability is regulated by UBR5-mediated ubiquitination (counteracted by CSN6) and OTUD1-mediated K63 deubiquitination.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDK9 is a nuclear, proline-directed serine/threonine kinase and the catalytic subunit of multimeric complexes whose principal cellular role is to release promoter-proximally paused RNA polymerase II into productive transcription elongation [#0, #1, #2, #14]. As the kinase of P-TEFb (with cyclin T), it phosphorylates the RNA Pol II CTD on serine 2 and is recruited to target genes such as p21 and HIV-1 LTR by sequence-specific factors and chromatin remodelers, where it shortens pause duration and increases productive initiation [#4, #8, #14]; at NELF-dependent paused genes its activity is a strict checkpoint required for productive elongation [#31]. CDK9 establishes substrate-specific kinase-phosphatase switches by inhibitory phosphorylation of PP1 and PP4, controlling both pause release and the elongation-to-termination transition through Spt5, and is dynamically opposed by INTS6-recruited PP2A on DSIF and the CTD [#22, #26, #27]. Through a large cohort of cellular substrates dominated by splicing factors (including SF3B1), CDK9 couples elongation to co-transcriptional RNA processing, polyadenylation, and splicing [#30, #27, #23]. Its activity is gated by inhibitory sequestration in the 7SK snRNP via HEXIM1/MAQ1 binding to cyclin T [#6] and by reversible modifications: SIRT7-mediated deacetylation (opposing GCN5) activates the kinase [#15], while SUMOylation\\u2014including TRIM28-catalyzed SUMOylation\\u2014blocks the CDK9\\u2013cyclin T1 interaction to suppress global and HIV-1 transcription [#17, #19]. CDK9 protein levels are set by ubiquitin-dependent turnover, with UBR5 promoting degradation (counteracted by CSN6) and OTUD1 stabilizing and activating CDK9 by K63 deubiquitination [#28, #33]. Beyond transcription, a distinct CDK9\\u2013cyclin K complex maintains genome integrity under replication stress in association with ATR [#12], CDK9 supports BRCA1/RAD51 focus formation and homologous recombination at DNA damage sites [#29], and it phosphorylates non-transcriptional targets including androgen receptor Ser81 and the p53 regulator Pirh2 [#11, #13].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established CDK9 as a nuclear CDC2-related kinase with substrate specificity distinct from CDC2, answering whether it was a generic cell-cycle CDK or a functionally separate enzyme.\",\n      \"evidence\": \"cDNA cloning, immunoprecipitation in vitro kinase assay, and immunofluorescence\",\n      \"pmids\": [\"8170997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates and partner subunits not yet identified\", \"The 80/95/155 kDa associated polypeptides not molecularly defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated CDK9 is the catalytic subunit of its complexes and a proline-directed Ser/Thr kinase whose activity is enhanced by associated regulatory proteins, defining it as a regulated holoenzyme.\",\n      \"evidence\": \"Catalytically inactive mutant reconstitution and in vitro phosphosite mapping\",\n      \"pmids\": [\"8870681\", \"9003389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the activating regulatory subunits (cyclins) not established\", \"In vivo substrates unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Linked CDK9 to gene-specific transcriptional activation by showing it is the catalytic subunit of Tat-associated kinase required for HIV-1 transactivation, with RNA-tethering sufficient to activate the LTR.\",\n      \"evidence\": \"Dominant-negative mutant, artificial RNA-tethering, and LTR reporter assays\",\n      \"pmids\": [\"9557739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CTD phosphorylation mechanism not yet shown\", \"Endogenous cellular promoters not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved subnuclear distribution by showing CDK9/cyclin T1 concentrate at splicing-factor-rich nuclear speckles in a transcription-dependent manner, hinting at coupling between elongation and RNA processing.\",\n      \"evidence\": \"High-resolution immunofluorescence with cyclin T1 deletion mapping and transcription inhibitors\",\n      \"pmids\": [\"11282025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of speckle localization not established\", \"Link to splicing only correlative at this stage\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined a dynamic inhibitory control mechanism by identifying HEXIM1/MAQ1 as a 7SK snRNA-dependent binder of cyclin T1 that competes with Tat, explaining how active P-TEFb is sequestered and released.\",\n      \"evidence\": \"Reciprocal co-IP, yeast two-hybrid, and transcription-inhibitor release assays\",\n      \"pmids\": [\"12832472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals triggering release from 7SK snRNP not defined\", \"Stoichiometry of the inactive complex unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed CDK9 expression and activity are constitutive across the cell cycle and not SCF(SKP2)-regulated, distinguishing it from oscillating cell-cycle CDKs.\",\n      \"evidence\": \"Synchronization, cycloheximide chase, SKP2 knockdown, and proteasome inhibition\",\n      \"pmids\": [\"12861003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E3 ligase governing endogenous turnover not identified here\", \"Discrepancy between endogenous and overexpressed protein stability unexplained\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected CDK9 to ordered gene activation by showing STAT3 recruits P-TEFb to phosphorylate Pol II CTD-Ser2 at p21 after BRG1-mediated chromatin remodeling.\",\n      \"evidence\": \"Co-IP, pull-down, and ChIP at the p21 promoter\",\n      \"pmids\": [\"15286705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab, two-method support\", \"Generality across STAT3 targets not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified two CDK9 isoforms (42k/55k) with identical CTD-kinase activity but distinct localization and differentiation-regulated expression, indicating isoform-specific deployment.\",\n      \"evidence\": \"Immunofluorescence, peptide-array kinase assays, and primary-cell/tissue immunoblotting\",\n      \"pmids\": [\"15452830\", \"15780980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct biological functions of the nucleolar 55k isoform not defined\", \"Mechanism directing differential localization unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended CDK9 substrate range beyond transcription machinery by identifying androgen receptor Ser81 as a site controlling AR promoter selectivity and growth.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, mass spectrometry, siRNA, and inhibitor/reporter assays\",\n      \"pmids\": [\"20980437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether P-TEFb or another CDK9 complex performs this phosphorylation in vivo not fully resolved\", \"Cyclin partner dependence not dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Distinguished a non-transcriptional CDK9 function by showing CDK9\\u2013cyclin K (not cyclin T) maintains genome integrity after replication stress in association with ATR.\",\n      \"evidence\": \"Cyclin-specific siRNA depletion, DNA damage assays, chromatin fractionation, and co-IP\",\n      \"pmids\": [\"21200140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CDK9-cyclin K substrates in the replication stress response not identified\", \"Mechanism of ATR cooperation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Implicated CDK9 in p53 stabilization by phosphorylating Pirh2 (Ser211/Thr217) to inactivate it and modifying Mdm2 to block p53 degradation.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, and site-directed mutagenesis\",\n      \"pmids\": [\"23603988\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, no independent replication\", \"Cellular relevance and cyclin partner not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Quantitatively dissected CDK9's elongation function, showing it shortens Pol II pause duration and increases productive initiation, and is linked to long-range chromatin interactions.\",\n      \"evidence\": \"Rapid chemical-genetic CDK9 inhibition in engineered cells with TT-seq, 4sU-seq, and Hi-C\",\n      \"pmids\": [\"28994650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal basis of the chromatin-interaction link not established\", \"Substrate(s) mediating initiation effects not pinpointed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed acetylation control of CDK9 activity, with SIRT7 deacetylating Lys48 to activate the kinase and promote 7SK release, opposing GCN5-mediated inhibitory acetylation.\",\n      \"evidence\": \"Substrate proteomics, in vitro deacetylation, CTD phosphorylation assays, and SIRT7 depletion\",\n      \"pmids\": [\"28426094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling the acetylation/deacetylation balance not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined CDK9 as a chromatin-silencing factor by showing CDK9 inhibition dephosphorylates BRG1 and reactivates epigenetically silenced tumor suppressors, expanding its role beyond elongation.\",\n      \"evidence\": \"Live-cell drug screen, siRNA, inhibitors, ChIP, and expression analysis in cancer models\",\n      \"pmids\": [\"30454645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRG1 phosphorylation directly mediates silencing not fully established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected CDK9 to homologous recombination by showing CDK9 interacts with BRCA1/BARD1 and is required for BRCA1 and RAD51 focus formation at DNA damage sites.\",\n      \"evidence\": \"Co-IP, IRIF imaging, siRNA knockdown, and HR/NHEJ repair assays\",\n      \"pmids\": [\"28278048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; direct kinase activity on repair factors not demonstrated\", \"Relationship to CDK9-cyclin K function unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established SUMOylation as an inhibitory switch by showing SUMO-modified CDK9 cannot bind cyclin T1, with MYC antagonizing this to amplify global transcription.\",\n      \"evidence\": \"SUMO-MS, SUMOylation assays, sumoylation-resistant mutant, and transcription profiling\",\n      \"pmids\": [\"29588524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO E3 ligase not identified in this study\", \"In vivo dynamics of CDK9 SUMOylation not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified TRIM28 as the SUMO ligase modifying CDK9 (Lys44/56/68 via SUMO4) that blocks P-TEFb assembly and enforces HIV-1 latency.\",\n      \"evidence\": \"Site-specific SUMO-MS, serial SUMOylation/kinase assays, co-IP, and mutagenesis\",\n      \"pmids\": [\"30652970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stimuli regulating TRIM28-CDK9 SUMOylation in latent cells not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Proposed additional CDK9 complexes (CTORC1/2 with mTOR scaffold mLST8) coupling CDK9 to transcription of leukemogenic genes and to translation via LARP1/rpS6.\",\n      \"evidence\": \"Interactome proteomics, co-IP, fractionation, and phosphorylation assays\",\n      \"pmids\": [\"30587525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, not independently replicated\", \"Direct kinase activity toward LARP1/rpS6 vs. scaffold role not fully distinguished\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Implicated CDK9 in circadian control by showing it associates with REV-ERB\\u03b1 and modulates Bmal1 promoter binding, with hypothalamic knockdown altering circadian physiology.\",\n      \"evidence\": \"siRNA screen, co-IP, and in vivo SCN knockdown with circadian phenotyping\",\n      \"pmids\": [\"31005255\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Whether the effect requires CDK9 kinase activity not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped the cellular CDK9 substrate landscape at proteome scale, revealing splicing factors as a dominant substrate class and establishing transcription-coupled splicing as a core CDK9 function.\",\n      \"evidence\": \"Analog-sensitive CDK9 with quantitative phosphoproteomics\",\n      \"pmids\": [\"31857848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of each substrate phosphorylation not individually validated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined CDK9 as the master kinase of dual kinase-phosphatase switches, inhibiting PP4 (pause release via Spt5) and PP1 (elongation-termination via Spt5 CTR) at distinct gene positions.\",\n      \"evidence\": \"Kinase-phosphatase depletion, phosphoproteomics, and ChIP-seq with Spt5 phospho-analysis\",\n      \"pmids\": [\"32859893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How position-specific phosphatase targeting is achieved not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed CDK9 inhibition globally impairs splicing and abolishes AR/AR-v7 expression, linking CDK9-dependent splicing to castration-resistant prostate cancer.\",\n      \"evidence\": \"RNA-seq, splicing analysis, CDK9 inhibition, and androgen deprivation assays\",\n      \"pmids\": [\"34592899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct splicing-factor substrates driving the effect not pinpointed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated CDK9 cooperation with H2B monoubiquitination to suppress intragenic antisense transcription, linking CDK9 to HDAC (Clr6-CII) recruitment and chromatin integrity in coding regions.\",\n      \"evidence\": \"Chemical-genetic Cdk9 inhibition, H2Bub1 epistasis, nascent RNA-seq, and ChIP-seq in fission yeast\",\n      \"pmids\": [\"32496538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CDK9 substrate mediating HDAC recruitment not identified\", \"Conservation in human cells not tested here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Suggested ASF1B as a stabilizing CDK9 partner that elevates CDK9 protein in cervical cancer.\",\n      \"evidence\": \"Co-IP, siRNA, overexpression, and xenografts\",\n      \"pmids\": [\"32848135\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Stability mechanism not confirmed with ubiquitin/proteasome assays\", \"Single co-IP, single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established INTS6-recruited PP2A as the dynamic antagonist of CDK9 on DSIF and the CTD, defining a tunable kinase-phosphatase balance exploitable therapeutically.\",\n      \"evidence\": \"INTS6 loss-of-function, substrate phosphoproteomics, PP2A activation, and in vivo tumor models\",\n      \"pmids\": [\"34004147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise recruitment mechanism of PP2A to transcription sites not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed CDK9 and PP2A act as opposing regulators of coupled elongation, termination, and RNA processing, with CDK9 inhibition causing premature termination and loss of SF3B1/polyadenylation factors rescued by PP2A inhibition.\",\n      \"evidence\": \"CDK9 and PP2A inhibition epistasis, ChIP-seq, metabolic RNA labeling, and chromatin occupancy\",\n      \"pmids\": [\"35980303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SF3B1 phosphosite causality not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a ubiquitin-based control of CDK9 abundance via the CSN6-UBR5 axis, with UBR5 promoting CDK9 degradation and CSN6 stabilizing it to drive melanoma.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, knockdown/overexpression epistasis, and xenografts\",\n      \"pmids\": [\"33483464\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin linkage type and degron not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed NELF-dependent pausing creates a strict requirement for CDK9 activity in pause release, explaining why CDK9 inhibition shuts down only NELF-paused genes.\",\n      \"evidence\": \"NELF depletion with chemical-genetic Cdk9 inhibition and nascent RNA-seq in Drosophila cells\",\n      \"pmids\": [\"37179384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the NELF-imposed checkpoint not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified the L156F kinase-domain mutation as a resistance mechanism to both ATP-competitive CDK9 inhibitors and PROTAC degraders via steric hindrance and altered stability.\",\n      \"evidence\": \"Acquired-resistance line, CRISPR knock-in, kinase and thermal shift assays\",\n      \"pmids\": [\"37719386\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Clinical prevalence of L156F not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed OTUD1 deubiquitinase activates CDK9 by K63-linked deubiquitination (via Cys320), driving inflammatory and fibrotic responses in kidney epithelium.\",\n      \"evidence\": \"Co-IP, deubiquitination assay with catalytic mutant, Otud1 knockout mice, and inhibitor treatment\",\n      \"pmids\": [\"38110583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How K63 deubiquitination mechanistically activates CDK9 kinase not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse non-canonical CDK9 complexes (cyclin K, CTORC, REV-ERB\\u03b1) are partitioned from P-TEFb and coordinated in vivo, and which post-translational and ubiquitin signals dominate in physiological versus disease contexts, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism selecting cyclin/scaffold partner for each CDK9 function unknown\", \"Integration of acetylation, SUMOylation, and ubiquitination control in a single cell not established\", \"Direct structural basis for substrate switching not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 11, 13, 22]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 14, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 14, 31]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [1, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 5, 9]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [5, 9]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [12, 18, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 8, 14, 31]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [23, 27, 30]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [12, 29]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [18, 24]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 19]}\n    ],\n    \"complexes\": [\"P-TEFb (CDK9-cyclin T)\", \"CDK9-cyclin K\", \"7SK snRNP\", \"CTORC1/CTORC2 (CDK9-mLST8)\"],\n    \"partners\": [\"CCNT1\", \"HEXIM1\", \"SIRT7\", \"TRIM28\", \"INTS6\", \"UBR5\", \"OTUD1\", \"BRCA1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}